NEW YORK (AdAge.com) -- TAP Pharmaceuticals said it put its account for heartburn drug Prevacid into review.

The incumbent agency on the account is Gillespie Healthcare, Princeton, N.J., part of Interpublic Group of Cos. Prior to Gillespie, the account was at Cordiant Communications Group's Bates USA, New York.

New direction

A TAP spokeswoman said the company has been happy with Gillespie, but is looking to evaluate whether it needs a new direction.

Gillespie could hold on to part of the business. The review includes media, creative and relationship marketing. The account generated $36.8 million in spending last year, according to Taylor Nelson Sofres' CMR.

Selecting agencies

The spokeswoman said request for proposals were due July 22 from holding companies WPP Group, Interpublic, Omnicom Group and Grey Global Group, which will choose agencies from within their networks to compete for the business.

TAP is based in Lake Forest, Ill., and is a joint venture between Abbott Laboratories and Takeda Chemical Industries.